This non-randomized cluster trial assessed the effectiveness of daily 20g SQ-LNS sachets combined with behavior change communication versus standard nutrition programming. The study population comprised 8,145 children aged 6 to 23 months in post-conflict settings of Tigray, Ethiopia, with 6,752 children in the intervention group and 1,393 in the control group. Follow-up occurred six months after initiation of the program.
Primary outcomes included acute malnutrition prevalence defined by weight-for-height z-scores (WHZ < -2) or mid-upper arm circumference (MUAC < 12.5cm) and the distribution of weight-for-height z-scores. In the intervention group, acute malnutrition prevalence declined from 22.2% to 4.6%, representing a 17.6 percentage point reduction. The control group experienced a reduction from 20.1% to 14.0%, a 6.1-point decrease. Using MUAC definitions, the net intervention effect demonstrated an 11.5-point reduction in prevalence.
Anthropometric improvements were also observed. Mean WHZ scores increased from -0.35 to +0.37 in the intervention group, compared to an increase from -0.79 to -0.63 in the control group, yielding a gain of +0.72 z-scores versus +0.16 in the control group. Mean MUAC increased significantly more in the intervention group, with a difference-in-difference of +5.03mm. The entire WHZ distribution shifted rightward in the intervention arm.
No adverse events, serious adverse events, discontinuations, or tolerability issues were reported. Key limitations include the non-randomized cluster trial design and the inherent constraints of evidence from post-conflict settings. Findings support the inclusion of SQ-LNS in post-conflict nutrition packages, though the non-randomized nature precludes definitive causal claims.
View Original Abstract ↓
IntroductionAcute malnutrition in children aged 6-23 months remains critical in Tigray, Ethiopia, where global acute malnutrition (GAM) rates have reached emergency levels. Small-quantity lipid-based nutrient supplements (SQ-LNS) show promise for prevention, but evidence from post-conflict settings is limited.
ObjectiveThis study evaluated SQ-LNS effectiveness in preventing acute malnutrition and rightward shifting in the distribution of weight-for-height among young children in post-conflict settings of Tigray, Ethiopia.
MethodsA non-randomized cluster trial enrolled 8,145 children aged 6-23 months across four districts. The intervention group (n=6,752) received daily 20g SQ-LNS sachets for six months plus behavior change communication; the control group (n=1,393) received standard nutrition programming. Primary outcomes were acute malnutrition prevalence (WHZ < -2 or MUAC < 12.5cm) and distribution of weight-for-height z-scores. Data were collected biweekly and analyzed using longitudinal comparisons and difference-in-differences (DiD) estimation.
ResultsAcute malnutrition declined from 22.2% to 4.6% in the intervention group (17.6 percentage point reduction) versus 20.1% to 14.0% in controls (6.1-point reduction). Mean WHZ scores increased from -0.35 to +0.37 in the intervention group (gain of +0.72 z-scores), while controls improved from -0.79 to -0.63 (gain of +0.16). The net intervention effect (DiD) showed a 4.1 percentage point reduction in WHZ-defined GAM and a 11.5-point reduction in MUAC-defined GAM. Mean WHZ and MUAC increased significantly more in the intervention group (DiD: +0.56 z-scores and +5.03mm, respectively). Critically, the entire WHZ distribution shifted rightward, indicating population-level nutritional improvement, not merely reduced caseloads.
ConclusionsSix months of daily SQ-LNS effectively prevented acute malnutrition and shifted the entire weight-for-height distribution rightward among young children in post-conflict settings of Tigray, Ethiopia. Benefits extended beyond treatment, lifting the whole child populations nutritional status. Findings support SQ-LNS inclusion in post-conflict nutrition packages and highlight the importance of assessing distributional outcomes, not just prevalence, when evaluating nutritional interventions.
Trial registration numberThis trial was registered at ClinicalTrials.gov, NCT06103084.